WASHINGTON, April 8, 2013 /PRNewswire/ -- EGMinistry of Health recently met with Dr. Gloria B. Herndon of GB Group Global in the nation's capital as part of Equatorial Guinea's efforts to drastically raise its standards of health care. These endeavors include building a pharmaceutical manufacturing facility in EG, implementing pharmaceutical quality control and policies, and exploring the release of a new treatment (Low Dose Naltrexone) against cancer and HIV/AIDS.

The purpose of the visit of Dr. Diosdado-Vicente Milang Nsue, the Delegate Minister of Health & Social Services and Dr. Consuelo Ondo Efua, the Director General of Drug Supply and Medical equipment, was to engage with organizations who through assistance, partnership and the sharing of best-practices could close medical knowledge gaps and help bring improved health care to Equatorial Guineans.

Among issues discussed, Minister Dr. Milang Nsue raised a problem rampant overseas: The need for affordable high quality medicines. "The devastating effects of substandard and counterfeit medicines in circulation lead to treatment failure, increased mortality and the development of drug resistance."

Dr. Milang stressed the fact that "...establishing in Equatorial Africa a pharmaceutical manufacturing facility with an analytical laboratory would be of paramount importance..." The proposed facility was part of conversations with TNI Biotech (OTCBB:TNIB), GB-Energie, GB-Pharma, Howard University and the United States Pharmacopeia representatives.

Dr. Ondo Efua said, "With the establishment of a drug manufacturing facility to treat the most current pathologies and a laboratory for drug quality control we could guarantee the safety and high quality of medicines either produced in EG or imported. We would have taken an important step to halt the traffic and commercialization of the counterfeit medicines that undermine the quality of the health services delivered to our population."

Further, as EG is concerned in the global struggle to combat the scourge of diseases such as HIV/AIDS and cancer, new developments regarding the therapy known as IRT-103 Low Dose Naltrexone were explained during the sessions.

Concluding the sessions, Dr. Herndon said she felt the exchanges had been productive and pleased that "...we (GB Group Global) were able to demonstrate our commitment to viable and sustainable solutions to the issues of the citizens well being and the growth of the nation."

www.gbenergie.com

SOURCE GB Group Global